GSK drug flops in leukemia PhIII; Prosecutors want tough Martoma sentence on insider trading;

@FierceBiotech: ICYMI Friday: Another Pfizer bid for AstraZeneca? Investors weigh in. Report | Follow @FierceBiotech

@JohnCFierce: So here's Jeff Stein's new company, Cidara--why all the hush-hush? Release | Follow @JohnCFierce

@DamianFierce: Fun with the U.K. takeover code: $ABBV's $46B bid is blocking $SHPG from shopping for itself. More | Follow @DamianFierce

@EmilyMFierce: Will Europe map the human brain faster than the U.S. can? More from Bloomberg | Follow @EmilyMFierce

> GlaxoSmithKline ($GSK) and its partner Genmab say that ofatumumab (Arzerra) failed a late-stage study for chronic lymphocytic leukemia. Investigators compared the drug against doctor's choice of drugs. Report

U.S. prosecutors are seeking a tough sentence against Mathew Martoma, the former SAC trader recently convicted of insider trading, saying the court's probation department had erred on the side of leniency when it suggested an 8-year prison sentence. Story

Merck ($MRK) says that its drug Emend proved effective in treating pediatric patients, preventing chemo-induced nausea and vomiting in a patient group ranging from 6 months to 17 years old. The drug is approved for adults. Release

Medical Device News

@FierceMedDev: ICYMI: Will Medtronic deal with Covidien benefit smaller players?  exec says yes. Article | Follow @FierceMedDev

@StacyALawrence: ICYMI: FDA clears first robotic exoskeleton for spinal cord injury patients. More | Follow @StacyALawrence

@VarunSaxena2: ICYM last week's feature: Top 10 Med Tech R&D Budgets. Special Report | Follow @VarunSaxena2

@MichaelGFierce: Intersect ENT files for $80M IPO to support steroid-delivering sinus implants. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce:  OKs first wearable motorized device that helps people with spinal cord injuries walk, More from the NYT | Follow @EmilyWFierce

> Study: One-third of knee replacements are inappropriate. Article

> Device for 'smart' kegel exercises to debut soon. More

> Researchers develop a durable hydrogel for use with implantable devices. Story

Pharma News

@FiercePharma: Top-read on FP this weekend: Sanofi's Lantus empire imperiled as EU recommends Lilly, Boehringer biosimilar. Article | Follow @FiercePharma

@TracyStaton: Here's @JohnCFierce's take on the Vertex VX-809/Kalydeco PhIII, including interview with CEO Jeff Leiden. Story | Follow @TracyStaton

@EricPFierce: This Indian pharma exec understands how to attain quality production & that many of his compatriots do not. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: Vertex could snag 250 more Kalydeco patients with EMA nod. Item | Follow @CarlyHFierce

> Wanted: Marketing strategy for MannKind's long-time-coming inhaled insulin. More

> Sex, bribes and videotape: Clandestine video of GSK exec adds to China scandal. Report

> Shire CEO's buyout plans thwarted when AbbVie came calling. Article

CRO News

> Recipharm and CTC unite for early-stage trials. Item

> Evotec pockets a payment in its Boehringer partnership. News

> ClinicalRM teams up with an Ohio network for clinical trials. More

> Bristol-Myers enlists Duke's CRO to help it share trial data. Report

> Parexel expects to hit the $2B mark in fiscal 2015. Article

> Covance is creating an OkCupid for molecules. Story

Biotech IT News

> Survey: Firms prioritizing data security over business-boosting analysis. Story

> U.K. scales back plans for patient database as docs back major revision. Report

> NIH aiming to lower IT barriers to 3D printing in drug research. More

> Experts warn FDA Twitter guidance will silence social conversation. Item

> Bristol-Myers strikes deal with Duke to open up trial data. Story

> Europe's brain project plans grant incentives to encourage data sharing. Article